Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits Acorda Therapeutics, 15 Apr 2013 Accessed on 26 Apr 2013 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1806488. CommentRecommendBookmarkWatch